Volociximab in cancer

Bibliography

• Abumiya T, Lucero J, Heo JH, Activated microvessels express vascular endothelial growth factor and integrin alphavbeta3 during focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:1038-50
   PubMed Web of Science ®Google Scholar
• Freije JM, Balbin M, Pendas AM, Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87
   PubMed Web of Science ®Google Scholar
• Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516-23
   PubMed Web of Science ®Google Scholar
• Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68
   PubMed Web of Science ®Google Scholar
• Francis SE, Goh KL, Hodivala-Dilke K, Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002;22:927-33
   PubMed Web of Science ®Google Scholar
• Robinson EE, Foty RA, Corbett SA. Fibronectin matrix assembly regulates alpha5beta1-mediated cell cohesion. Mol Biol Cell 2004;15:973-81
   PubMed Web of Science ®Google Scholar
• Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha5 integrin-deficient mice. Development 1993;119:1093-105
   PubMed Web of Science ®Google Scholar
• Kim S, Harris M, Varner JA. Regulation of integrin alphavbeta3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000;275:33920-8
   PubMed Web of Science ®Google Scholar
• Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994;269:24756-61
   PubMed Web of Science ®Google Scholar
• Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62
   PubMed Web of Science ®Google Scholar
• Beauvais A, Erickson CA, Goins T, Changes in the fibronectin-specific integrin expression pattern modify the migratory behavior of sarcoma S180 cells in vitro and in the embryonic environment. J Cell Biol 1995;128:699-713
   PubMed Web of Science ®Google Scholar
• Gong J, Wang D, Sun L, Role of alpha5beta1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997;8:83-90
   PubMedGoogle Scholar
• Qian F, Zhang ZC, Wu XF, Interaction between integrin alpha5 and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005;333:1269-75
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science 1994;264:569-71
   PubMed Web of Science ®Google Scholar
• Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 1999;112:569-78
   PubMed Web of Science ®Google Scholar
• Senger DR, Ledbetter SR, Claffey KP, Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305
   PubMed Web of Science ®Google Scholar
• Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. J Biol Chem 2004;279:4862-8
   PubMed Web of Science ®Google Scholar
• Kim S, Bakre M, Yin H, Varner JA. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002;110:933-41
   PubMed Web of Science ®Google Scholar
• Barkan D, Chambers AF. beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011;17:7219-23
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Bhaskar V, Law DA, Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86
   PubMedGoogle Scholar
• Ricart AD, Tolcher AW, Liu G, Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a Phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-9
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Cranmer L, Hodi S, A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. J Clin Oncol 2008;26(20 Suppl):abstract 9051
   Google Scholar
• Cranmer LD, Bedikian AY, Ribas A, Phase II study of volociximab (M200), an alpha5beta1 anti-integrin antibody in metastatic melanoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18 Suppl 20):8011
   Google Scholar
• Evans T, Valle J, Berlin J, Ramanathan Interim results from a phase II study of volociximab in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer [abstract # 142]. 2008 ASCO Gastrointesintal Cancer Symposium
   Google Scholar
• Evans T, Ramanathan RK, Yazji S, Final results from cohort 1 of a phase II study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18 Suppl 20):4549
   Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32
   PubMed Web of Science ®Google Scholar
• Figlin RA, Kondagunta GV, Yazji S, Phase II study of volociximab (M200), an alpha5beta1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18 Suppl 20):4535
   Google Scholar
• Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an alpha5beta1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18 Suppl 20):5094
   PubMedGoogle Scholar
• Markowska J, Szala S. Inhibitors of angiogenesis in therapy of ovarian cancers. Eur J Gynaecol Oncol 2004;25:562-7
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995;91:229-34
   PubMed Web of Science ®Google Scholar
• Sawada K, Mitra AK, Radjabi AR, Loss of E-cadherin promotes ovarian cancer metastasis via alpha5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-39
   PubMed Web of Science ®Google Scholar
• Bell-McGuinn KM, Matthews CM, Ho SN, A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273-9
   PubMed Web of Science ®Google Scholar
• Vergote IB, Colombo N, Kutarska E, Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2009;27(15 Suppl):abstract 5560
   Google Scholar
• Adachi M, Taki T, Higashiyama M, Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HS, Lee SH, Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003;41:65-70
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Besse B, Soria JC, Chico I, Volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2009;7(2 Suppl):547
   Google Scholar